Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504818 | 0.90 | CNR1 (0.63) | CNR1CNR2RXFP1 | |
| SCHEMBL6105921 | 0.90 | CNR1 (0.53) | CNR1CNR2HTR2AHTR2CRXFP1 | |
| SCHEMBL4508459 | 0.83 | HTR2A (0.54) | CNR1CNR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL6105918 | 0.80 | CNR1 (0.63) | CNR1CNR2RXFP1 | |
| SCHEMBL4511315 | 0.79 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL4510012 | 0.79 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL4497043 | 0.79 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL4508622 | 0.78 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL4505931 | 0.78 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL4491084 | 0.74 | CNR1 (0.58) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | claimed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | claimed |
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885HTR2A 284/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885HTR2A 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.